Clinical study of Qidongyixin oral liquid improve chemotherapy of malignant tumor related heart qi deficiency syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17010752

Enrollment

Unknown

Registered

2017-02-28

Start date

2017-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

treatment group:Qidongyixin oral liquid

control group:Shengmai Decoction

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. 2 months after the last chemotherapy of malignant tumor; 2. No chemotherapy plan was planned for 14 days; 3. Syndrome of deficiency of heart qi; 4. Aged 40-75 years old; 5. KPS=60; 6. Expected survival of more than 3 months; 7. No serious damage of lung and kidney function; 8. NYHA = level 2; 9. HGB =7g/L.

Exclusion criteria

Exclusion criteria: 1. Mental disorders can not accurately express subjective symptoms; 2. With severe uncontrolled medical conditions; 3. Pregnant or lactating women; 4. Poor medication compliance was found in past treatment history.

Design outcomes

Primary

Measure	Time frame
palpitate;Shortness of breath;weak;Sweat;insomnia;	—

Secondary

Measure	Time frame
Routine blood test;liver function;kidney function;ECG;Echocardiography;Myocardial enzyme spectrum;	—

Countries

China

Contacts

Public ContactXinyi Chen

Dongzhimen hospital affilisted to Beijing university of Chinese Medicine

chenxinyi0729@126.com+86 13601008250

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026